Brain infarction, or stroke, is caused by a blood clot blocking a blood vessel in the brain, which leads to interruption of blood flow and shortage of oxygen. Now a research group at Lund University, Sweden, has taken an important step towards a treatment for stroke using stem cells.
The group shows in a new study that induced pluripotent stem cells have developed to mature nerve cells at two months after transplantation into the stroke-injured cerebral cortex of rats. These nerve cells have established contact with other important structures in the brain. The transplantation gave rise to improvement of the animals
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:18Important step towards stem cell-based treatment for stroke
A new study of electronic intensive care units (eICUs) shows them to be an effective way to provide 24-hour intensive care to patients in remote locations. An eICU uses telecommunications technology to diagnose and treat patients in the ICU remotely. Using two-way cameras, video monitors, microphones, and alarms to provide round-the-clock care for patients in ICUs, eICUs can provide care to patients in multiple hospitals, using the skills of intensive care physicians, called intensivists, and intensive care nurses. Researchers at Northside Medical Center in Ohio studied results of interactions with 2,537 patients admitted to ICUs over a period of 2 years. Of these interactions, 1,310 patients were without eICU monitoring and 1,227 were monitored with eICU in addition to in-house monitoring of medical staff. The eICU used intensivists and other healthcare providers to give continuous monitoring and management from a remote location in two adult ICUs of a 375-bed community teaching hospital in the United States. Results were taken on the rate of falls, incidences of code blues, (a hospital code used to indicate a patient requiring immediate resuscitation), mortalities, and length of stays between the two periods before and aft er implementation of the eICU. Specific outcomes encountered by patients with normal vs eICU monitoring showed code blues 54 vs 39, falls 1 vs 0, and overall mortality 90 vs 77. The median length of stay was 3.1 days without eICU monitoring and 3 days with eICU monitoring.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:06Electronic intensive care units (eICUs) effective in providing remote care
A team of researchers at the University of Twente in the Netherlands have developed a prototype of a new imaging tool that may one day help to detect breast cancer early, when it is most treatable.
If effective, the new device, called a photoacoustic mammoscope, would represent an entirely new way of imaging the breast and detecting cancer. Instead of X-rays, which are used in traditional mammography, the photoacoustic breast mammoscope uses a combination of infrared light and ultrasound to create a 3-D map of the breast.
In the new technique, infrared light is delivered in billionth-of-a-second pulses to tissue, where it is scattered and absorbed. The high absorption of blood increases the temperature of blood vessels slightly, and this causes them to undergo a slight but rapid expansion. While imperceptible to the patient, this expansion generates detectable ultrasound waves that are used to form a 3-D map of the breast vasculature. Since cancer tumours have more blood vessels than the surrounding tissue, they are distinguishable in this image.
Currently the resolution of the images is not as fine as what can be obtained with existing breast imaging techniques like X-ray mammography and MRI. Future versions are expected to improve the resolution as well as add the capability to image using several different wavelengths of light at once, which is expected to improve detectability.
The Twente researchers, who belong to the Biomedical Photonic Imaging group run by Professor Wiendelt Steenbergen, have tested their prototype in the laboratory using phantoms
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:13Imaging breast cancer with light
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:20Cry analyser seeks clues to babies? health
Diabetes Mellitus, a metabolic disorder that affects nearly 170 million people worldwide, is characterised by chronic hyperglycaemia that disrupts carbohydrate fat and protein metabolism resulting from defects in insulin secretion, insulin action or both. DM can cause long-term damage, dysfunction and even failure of various organs.
Patients with DM may develop corneal complications and delayed wound healing. This slow wound healing contributes to increased infections and the formation of bed sores and ulcers. Corneal complications include diabetic neuropathies and ocular complications that often lead to reduced vision or blindness.
A team of Wayne State University researchers recently developed several diabetic models to study impaired wound healing in diabetic corneas. Using a genome-wide cDNA array analysis, the group identified genes, their associated pathways and the networks affected by DM in corneal epithelial cells and their roles in wound closure. The findings may bring scientists one step closer to developing new treatments that may slow or thwart DM
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:08Researcher discovers new treatment for skin and corneal wound healing in diabetics
A team of scientists led by researchers from the University of California, San Diego School of Medicine and Ludwig Institute for Cancer Research have identified a novel therapeutic approach for the most frequent genetic cause of ALS, a disorder of the regions of the brain and spinal cord that control voluntary muscle movement, and frontotemporal degeneration, the second most frequent dementia.
The study establishes using segments of genetic material called antisense oligonucleotides
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:15New therapeutic target identified for ALS and frontotemporal degeneration
A highly targeted cancer radiation therapy may offer a safe and effective treatment option for elderly pancreatic cancer patients unable to undergo surgery or combined chemotherapy and radiation therapy, according to researchers at Henry Ford Hospital in Detroit.
Called stereotactic body radiotherapy (SBRT), the study finds patients lived, on average, six to seven months longer following treatment with minimal side-effects even when they had other severe comorbidities such as chronic obstructive pulmonary disease (COPD), heart disease and diabetes.
Two of the patients in the study lived nearly two years.
‘Elderly individuals, those ages 75 and older, account for approximately 40 percent of patients diagnosed with pancreatic cancer,’ says study lead author Raphael Yechieli, M.D., with the Department of Radiation Oncology at Henry Ford Hospital.
‘These patients are too ill to receive any other treatment, but with stereotactic body radiotherapy we
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:23Targeted radiation therapy safe, effective for elderly patients
Researchers from the University of Dundee have developed a new strategy for prescribing antibiotics that could reduce patient harm and help combat the rise in antibiotic resistance.
A new study found that a new prescribing protocol could significant reduce potential misuse of antibiotics.
The research followed over 500 patients with lower respiratory tract infections during the course of one year. The new prescribing protocol included automatic stop dates, with time limits on prescriptions depending on the severity of an infection, coupled with support from pharmacists to ensure that antibiotics were issued with stop dates that were clearly visible for patients.
During the first half of the 12-month trial, researchers monitored patients’ current duration of antibiotic use. In the second half, patients receiving antibiotics followed the new prescribing strategy. During both phases of this study, researchers monitored antibiotic side-effects, including new symptoms occurring during the period of antibiotic exposure that were potentially caused by the antibiotics. They also monitored patients’ length of stay in hospital and death rates.
The study found that when the new protocol was followed, there was a near 20 per cent reduction in antibiotic use and an associated 40 per cent reduction in antibiotic-related side-effects.
Dr Matthew Lloyd, lead author from the University’s School of Medicine, said, ‘The threat from growing resistance to antibiotics is increasing, which is in part attributable to inappropriately lengthy courses of antibiotics.
‘Our study aimed to implement a simple system for preventing patients taking antibiotics for longer than they should. The results were promising and found that through prescribing automatic stop dates and working with our multidisciplinary colleagues, we can help prevent this problem and reduce patient harm.’
University of Dundee
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:25New strategy could reduce inappropriate use of antibiotics
The benefits of hydroxyurea treatment in people with sickle cell disease are well known
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:11Drug treatment means better, less costly care for children with sickle cell disease
Doctors have been urged to change how they prescribe medicines to stop
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:41:042020-08-26 14:41:18Doctors urged to cut medicine prescription waste
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.